102 related articles for article (PubMed ID: 1102163)
1. Observations in immunotherapy of lymphoma and melanoma patients.
Thomas JW; Plenderleith IH; Clements DV; Landi S
Clin Exp Immunol; 1975 Jul; 21(1):82-96. PubMed ID: 1102163
[TBL] [Abstract][Full Text] [Related]
2. [Immunological reactions of skin melanoma patients to nonspecific and adaptive immunotherapy].
Trapeznikov NN; Iavorskiĭ VV; Kadagidze ZG; Malaev SG; Kupin VI
Vopr Onkol; 1977; 23(8):27-33. PubMed ID: 906404
[TBL] [Abstract][Full Text] [Related]
3. BCG immunotherapy in previously treated malignant melanoma patients.
Mujagić H; Kolarić K; Malenica B; Nola P
Biomedicine; 1979 Jun; 30(2):95-102. PubMed ID: 476270
[TBL] [Abstract][Full Text] [Related]
4. Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma.
Di Nicola M; Carlo-Stella C; Mortarini R; Baldassari P; Guidetti A; Gallino GF; Del Vecchio M; Ravagnani F; Magni M; Chaplin P; Cascinelli N; Parmiani G; Gianni AM; Anichini A
Clin Cancer Res; 2004 Aug; 10(16):5381-90. PubMed ID: 15328176
[TBL] [Abstract][Full Text] [Related]
5. Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanoma.
Ridolfi L; Ridolfi R
Hepatogastroenterology; 2002; 49(44):335-9. PubMed ID: 11995445
[TBL] [Abstract][Full Text] [Related]
6. [Immunotherapy of malignant melanoma (active specific and non-specific immune stimulation) (author's transl)].
Kokoschka EM; Micksche M
Wien Klin Wochenschr; 1976 Nov; 88(21):690-6. PubMed ID: 1007279
[TBL] [Abstract][Full Text] [Related]
7. Sequential examination of lymphocyte proliferative capacity in patients with malignant melanoma receiving BCG immunotherapy.
Golub SH; Forsythe AB; Morton DL
Int J Cancer; 1977 Jan; 19(1):18-26. PubMed ID: 137880
[TBL] [Abstract][Full Text] [Related]
8. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
[TBL] [Abstract][Full Text] [Related]
9. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
10. [Studies on the immune status of melanoma patients: cell-mediated immune reactions in intracutaneous and epicutaneous tests in the lymphocyte transformation test and the leukocyte-migration inhibition test before and during BCG immunotherapy (author's transl)].
Knopf B; Wätzig V; Knöll B
Arch Geschwulstforsch; 1978; 48(8):722-8. PubMed ID: 753194
[TBL] [Abstract][Full Text] [Related]
11. Intralesional BCG application in malignant melanoma.
Sopková B; Kolár V
Neoplasma; 1976; 23(4):421-6. PubMed ID: 794745
[TBL] [Abstract][Full Text] [Related]
12. [Response in patients with melanoma to immunization using melanoma oncolysates of vaccine virus].
Doré JF; Portoukalian J; Berthier-Vergnes O; Jacubovich R; Genève J; Bailly M; Lefthériotis E; Weissbrod A; Mayer M
Bull Cancer; 1990; 77(9):881-91. PubMed ID: 2224160
[TBL] [Abstract][Full Text] [Related]
13. Effects of BCG and Corynebacterium parvum on immune reactivity in melanoma patients.
Thatcher N; Crowther D
Dev Biol Stand; 1977 Apr 13-15; 38():449-53. PubMed ID: 608536
[TBL] [Abstract][Full Text] [Related]
14. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL
Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
[TBL] [Abstract][Full Text] [Related]
15. Antibody responses to Bacillus Calmette-Guérin during immunotherapy in bladder cancer patients.
Winters WD; Lamm DL
Cancer Res; 1981 Jul; 41(7):2672-6. PubMed ID: 7018669
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma.
Mastrangelo MJ; Maguire HC; Eisenlohr LC; Laughlin CE; Monken CE; McCue PA; Kovatich AJ; Lattime EC
Cancer Gene Ther; 1999; 6(5):409-22. PubMed ID: 10505851
[TBL] [Abstract][Full Text] [Related]
17. Immunological factors which influence response to immunotherapy in malignant melanoma.
Morton D; Eilber FR; Malmgren RA; Wood WC
Surgery; 1970 Jul; 68(1):158-63; discussion 163-4. PubMed ID: 10483463
[TBL] [Abstract][Full Text] [Related]
18. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant.
Mitchell MS; Kan-Mitchell J; Kempf RA; Harel W; Shau HY; Lind S
Cancer Res; 1988 Oct; 48(20):5883-93. PubMed ID: 3262416
[TBL] [Abstract][Full Text] [Related]
19. Immunological changes in cancer patients receiving BCG.
Cochran AJ; Mackie RM; Jackson AM; Ogg LJ; Ross CE
Dev Biol Stand; 1977 Apr 13-15; 38():441-8. PubMed ID: 608535
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Wiernik PH; Lossos IS; Tuscano JM; Justice G; Vose JM; Cole CE; Lam W; McBride K; Wride K; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Habermann TM
J Clin Oncol; 2008 Oct; 26(30):4952-7. PubMed ID: 18606983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]